Atebrioz (zilurgisertib)

Fibrodysplasia ossificans progressiva

Also known as INCB000928

Manufacturer: Mirum Pharmaceuticals
Regulatory submission: NDA submitted by May 2026
Launch: Anticipated in October 2026
Last updated: October 1, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Current treatment options and standard of care

37 evidence topics · 18 sources

Retinoic acid receptor gamma agonists10 evidence topics · 7 sources
Activin A monoclonal antibodies4 evidence topics · 5 sources
Corticosteroids for flare-ups4 evidence topics · 1 source
Nonsteroidal anti-inflammatory drugs and COX-2 inhibitors4 evidence topics · 2 sources
Off-label therapies5 evidence topics · 4 sources
Injury prevention and supportive care5 evidence topics · 1 source
Limitations of current therapies5 evidence topics · 9 sources